END TO END SERVICE
For Referring Partners
Partner with us
At StoreGene, we offer cutting-edge, clinically validated whole genome sequencing services designed to seamlessly integrate with and enhance your existing health and wellness offering. Whether you are an independent practitioner or represent a specialised patient support group looking to expand into personalised medicine, genetic screening, or preventative health, we’re here to support your growth with precision and care.
Benefits
Access to Whole Genome Sequencing (WGS)
Offer your clients the most comprehensive form of genetic testing available.
Trade Pricing on Sequencing
Benefit from exclusive partner rates, improving your margins and making WGS more accessible.
Partner Royalty Scheme
Earn royalties for contributing to or co-developing new analyses and reports, fostering true collaboration.
Full Range of Genomic Analyses
From monogenic conditions to polygenic risk scores, pharmacogenomics, nutrigenomics, and beyond. If it exists, we can deliver it.
End-to-End Service
We manage the entire process — from sample collection and logistics, to sequencing, analysis, interpretation, secure data storage, and report delivery
Scientifically and Clinically Robust:
Our services are underpinned by a strong foundation in genomics research, clinical best practice, and ethical data handling.
Current Partners
Lycenna is a Swedish healthcare company founded in 2022, offering personalised medical concierge services. Based in Stockholm, the company provides clients with 24/7 access to a dedicated team of physicians, comprehensive genetic screening for disease risk and prevention, and global health insurance options through strategic partnerships. Lycenna’s approach emphasises proactive, tailored healthcare supported by a network of leading medical specialists worldwide.
maMEDS is a Greek digital health startup founded in 2024 that aims to improve medication adherence through technology and personalised support. Co-founded by pharmacist Ioannis Alafakis and bioinformatician Dr. Theodosia Charitou, the company emerged in response to challenges highlighted during the COVID-19 pandemic. maMEDS is part of Elevate Greece and has been recognised in various health innovation programs.
FiiHii is a London-based wellness company founded in 2024 by Carl Joyce, offering nutrient-rich smoothies called Frinks® designed to enhance gut health, mental clarity, and overall well-being. The company’s mission is rooted in Joyce’s personal experiences with health challenges, leading to a focus on the gut-brain connection and the importance of whole-food nutrition. FiiHii emphasises clean, additive-free products and offers various subscription plans to make healthy eating accessible and sustainable
Professor Riyaz Patel
CLINICAL CARDIOLOGIST
Professor Riyaz Patel is a consultant cardiologist and professor at UCL, with expertise in advanced cardiac imaging, cholesterol disorders, and genetically driven heart disease. He leads research into coronary artery disease genetics as a BHF clinician scientist and has established a cardiovascular prevention service at Barts Heart Centre. Clinically, he manages a wide range of heart conditions and is accredited in advanced echocardiography and cardiac CT angiography.
Dr Anna Sanniti
NUTRITIONAL GENETICIST
With a PhD in genomics from the University of Oxford and a background in biomedical science, pharmacogenetics, and nutritional therapy, Anna takes a root-cause, research-led approach to health. She helps men and women regain vitality by addressing symptoms through personalised nutrition, functional testing, and a whole-body focus — often starting with the gut. Based in Brighton, Anna offers one-to-one consultations both online and in person, combining scientific rigour with a compassionate, holistic approach.
Dr Melita Irving, PhD
RARE DISEASE SPECIALIST
Dr. Melita Irving is a London-based clinical geneticist and honorary reader, specializing in rare genetic and skeletal disorders. With a background in paediatrics, she leads multidisciplinary clinics for skeletal dysplasia and is a chief investigator in related clinical trials. An active researcher and author of The Human DNA Manual, she was recognized with a GHP Private Healthcare Award in 2019.
StoreGene’s Clinical Genomic Operating System makes it faster, cheaper and easier to apply whole genome data into actionable clinical insights
OUR METHOD
Utilising the Whole Genome
At StoreGene, we analyse whole genome data. Our incredible bioinformatic pipelines allow you to surface variants from all regions of the genome, and our simple reanalysis process allows you to use the most up-to-date clinical research to inform your decision-making.
Rapid Turnaround Time
From sample extraction to analysis and finished report, our Whole Genome Sequencing process can be carried out in just 30 days. For reanalysis, this is reduced to just 7 days.
Increased Diagnostic Yield
Over a large number of studies, the diagnostic yield attained by WES ranges between 25 and 50%, while the WGS diagnostic yield is about 40–60%.
Medication management
99.7% of people have a genetic variation which alters how they metabolise common medications. By using pharmacogenomic data you can reduce adverse drug reactions by 30%.
Always Clinician-led
We believe that no individual should be presented with a genetic report without being provided with clinical guidance and context. Our reports are always shared with the clinician first, and released to the patient after consultation.
OUR VISION
The power of reanalysis
In the last 3 years alone, researchers have identified over 70,000 new pathogenic variants. With approximately 60 new disease-causing variants being discovered daily, reanalysis is a vital part of clinical care. The beauty of StoreGene is that there is no need to order another test, and no additional sample is required. Simply specify your area of analysis and we’ll take care of the rest
